Research

• 

  Analyst Research

  Tetra Bio-Pharma (OTC: TBPMF): Could This $0.20 stock targeting the $70+ billion pain management market be worth $10.00+ in the next 18 months?

  August 2, 2021

  Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) Current Price (8/3/21) $0.20 Upside Potential Target: $10.00 Next 18 months.   Tetra Bio-Pharma (OTC: TBPMF), (TSX: TBP) has a robust clinical pipeline that targets markets valued at more than of $250B combined   TBPMF should be trading at $2.00+ right now based on typical valuations of  companies in FDA Phase 2 trials which target massive market opportunities like pain management. Accelerated FDA clinical trials with Fast Track and Orphan Drug Designations could take TBPMF to $2.50 within next 6-9 months   FDA approval of QIXLEEF is potential catalyst to send TBPMF to $10.00 driven by QUIXLEEF’s commercialization potential as opioid alternative, and $70 billion market opportunity – in addition to “halo effect” driving market enthusiasm for rest of TBPMF’s pipeline    Pain management market valued at $70B in 2021 and expected to grow to over $77B by 2023 – TBPMF offers revolutionary alternative to [...]

• 

  Analyst Research

  Logiq (OTC: LGIQ): Global Ecommerce and Fintech Enabler with 10X Upside Potential

  July 30, 2021

  Logiq (OTC: LGIQ) (NEO: LGIQ) Current Price: $2.75 (July 30, 2021) Upside Potential Target: $20.00-30.00 – 12 months Investment Concept: Logiq (OTC: LGIQ) (NEO: LGIQ) is a global e-commerce and fintech enabler which is deeply undervalued in relation to it’s peer group, and offers +7X upside appreciation potential as this vaaluation gap closes. LGIQ generated $37.9 million revenues in 2020, and  currently trading at a market cap of just $75 million. This is a multiple of less than 2X revenues. By comparison most of LGIQ’s peer group trades at multiples of 10-20X revenues. Even if LGIQ were to trade at the low-end of this valuation range – 10X revenues, this would place LGIQ at $20.00+ today. Additional upside potential as LGIQ accelerates revenue to $100 million+ run-rate via M&A, in next 12 months – which could send shares to $30+ (Based on 10X revenue multiple and projected 33 million shares [...]